Published in J Clin Oncol on May 11, 2009
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol (2009) 2.07
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2015) 1.67
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer (2013) 1.31
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest (2011) 1.28
Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther (2010) 1.07
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther (2012) 1.05
First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine (2013) 0.98
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist (2010) 0.96
Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist (2010) 0.94
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer (2013) 0.89
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther (2011) 0.87
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract (2012) 0.85
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer (2013) 0.85
Maintenance therapies for non-small cell lung cancer. Front Oncol (2014) 0.82
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer (2010) 0.82
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist (2015) 0.81
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol (2014) 0.80
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol (2010) 0.80
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol (2014) 0.80
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs (2012) 0.79
Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol (2009) 0.79
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs (2013) 0.78
Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma. Sultan Qaboos Univ Med J (2013) 0.78
Surgical treatment of stage IV non-small cell lung cancer. Interact Cardiovasc Thorac Surg (2011) 0.78
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. Oncol Lett (2014) 0.77
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol (2016) 0.77
Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). Sultan Qaboos Univ Med J (2013) 0.76
Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol (2012) 0.76
Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience. Drugs R D (2012) 0.76
Pemetrexed-Induced Nephrogenic Diabetes Insipidus. Am J Kidney Dis (2016) 0.75
Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clin Lung Cancer (2015) 0.75
Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett (2016) 0.75
Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf (2012) 0.75
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review. Medicine (Baltimore) (2016) 0.75
The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and Staging. Tanaffos (2013) 0.75
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. J Thorac Oncol (2016) 0.75
Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Transl Lung Cancer Res (2017) 0.75
Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget (2017) 0.75
Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. Int J Clin Oncol (2014) 0.75
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med (2015) 6.04
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol (2008) 3.99
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74
Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics (2009) 3.29
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol (2003) 2.68
Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst (2004) 2.37
Colorectal cancer screening knowledge, attitudes, and beliefs among veterans: does literacy make a difference? J Clin Oncol (2004) 2.27
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res (2010) 1.94
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol (2007) 1.86
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2004) 1.82
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol (2013) 1.75
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.74
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res (2013) 1.70
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol (2006) 1.58
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol (2004) 1.56
Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol (2005) 1.55
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther (2010) 1.55
The northwestern anagram test: measuring sentence production in primary progressive aphasia. Am J Alzheimers Dis Other Demen (2009) 1.55
Developing an effective and compliant plan for billing clinical trials. J Oncol Pract (2006) 1.49
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma (2014) 1.47
Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg (2006) 1.43
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.43
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol (2004) 1.42
Neurology of anomia in the semantic variant of primary progressive aphasia. Brain (2009) 1.39
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol (2004) 1.37
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology (2007) 1.36
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys (2003) 1.33
alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2007) 1.29
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer (2010) 1.28
Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain (2012) 1.26
Words and objects at the tip of the left temporal lobe in primary progressive aphasia. Brain (2013) 1.26
A randomized study comparing the Shaker exercise with traditional therapy: a preliminary study. Dysphagia (2009) 1.23
Human male recombination maps for individual chromosomes. Am J Hum Genet (2004) 1.21
TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol (2010) 1.19
Dissociations Between Fluency And Agrammatism In Primary Progressive Aphasia. Aphasiology (2012) 1.17
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest (2007) 1.16
Laryngeal penetration during deglutition in normal subjects of various ages. Dysphagia (2006) 1.16
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol (2007) 1.14
Development of a brief survey on colon cancer screening knowledge and attitudes among veterans. Prev Chronic Dis (2005) 1.13
Literacy barriers to colorectal cancer screening in community clinics. J Health Commun (2012) 1.10
Rationale and design of a randomized trial to evaluate an evidence-based prescription drug label on actual medication use. Contemp Clin Trials (2010) 1.08
Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging (2008) 1.08
Variation in MLH1 distribution in recombination maps for individual chromosomes from human males. Hum Mol Genet (2006) 1.06
Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. Neuropathology (2012) 1.06
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol (2006) 1.05
Augmentation of deglutitive thyrohyoid muscle shortening by the Shaker Exercise. Dysphagia (2008) 1.05
The mini-mental state examination in behavioral variant frontotemporal dementia and primary progressive aphasia. Am J Alzheimers Dis Other Demen (2008) 1.02
Multifocal presentation of gangliocytic paraganglioma in the mediastinum and esophagus. Hum Pathol (2004) 1.02
Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.01
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.01
CFS prevalence and risk factors over time. J Health Psychol (2011) 1.01
Profiles of decline in activities of daily living in non-Alzheimer dementia. Alzheimer Dis Assoc Disord (2007) 1.00
Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol (2008) 0.99
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol (2007) 0.99
Variation in meiotic recombination frequencies among human males. Hum Genet (2004) 0.99
Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol (2014) 0.99
Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol (2003) 0.98
Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol (2011) 0.98
Clinical statement on the role of the surgeon and surgical issues relating to computed tomography screening programs for lung cancer. Ann Thorac Surg (2013) 0.98
Improving mammography screening among the medically underserved. J Gen Intern Med (2013) 0.98
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma (2009) 0.98
Covert processing of words and pictures in nonsemantic variants of primary progressive aphasia. Alzheimer Dis Assoc Disord (2008) 0.97
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol (2013) 0.97
The impact of robotics on practice management of endometrial cancer: transitioning from traditional surgery. Int J Med Robot (2009) 0.96
High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol (2009) 0.96
Time from diagnosis to definitive operative treatment of operable breast cancer in the era of multimodal imaging. Surgery (2010) 0.96
Vasectomy in men with primary progressive aphasia. Cogn Behav Neurol (2006) 0.96
Abnormal progression through meiosis in men with nonobstructive azoospermia. Fertil Steril (2006) 0.96
Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril (2011) 0.96
Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer (2010) 0.95
Reproducibility of ductal lavage cytology and cellularity over a six month interval in high risk women. Breast Cancer Res Treat (2007) 0.95
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol (2012) 0.95
Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res (Phila) (2009) 0.95
Metastatic glioblastoma: case presentations and a review of the literature. J Neurooncol (2011) 0.95
Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis (2011) 0.94
A predictive model to identify hospitalized cancer patients at risk for 30-day mortality based on admission criteria via the electronic medical record. Cancer (2013) 0.93
Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen (2011) 0.93
Quantification of cervical spine muscle fat: a comparison between T1-weighted and multi-echo gradient echo imaging using a variable projection algorithm (VARPRO). BMC Med Imaging (2013) 0.93
Word list versus story memory in Alzheimer disease and frontotemporal dementia. Alzheimer Dis Assoc Disord (2006) 0.93
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol (2008) 0.93
ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias. Alzheimer Dis Assoc Disord (2011) 0.93
Improving colon cancer screening in community clinics. Cancer (2013) 0.93
Low Tidal Volume Ventilation Use in Acute Respiratory Distress Syndrome. Crit Care Med (2016) 0.92
Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol (2004) 0.92
Implementation of the federal excise tax on indoor tanning services in Illinois. Arch Dermatol (2012) 0.92
Strategies to improve repeat fecal occult blood testing cancer screening. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 0.91
Rate of cognitive change measured by neuropsychologic test performance in 3 distinct dementia syndromes. Alzheimer Dis Assoc Disord (2007) 0.91
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol (2007) 0.91